Pasar al contenido principal

DESCUBRIMIENTO DE FARMACOS MULTIDIANA CONTRA ENFERMEDADES NEURODEGENERATIVAS POR MODULACION DE DIANAS NO CONVENCIONALES

PID2021-124983OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Network-Based Drug Optimization toward the Treatment of Parkinson’s Disease: NRF2, MAO-B, Oxidative Stress, and Chronic Neuroinflammation

  • Duarte, Pablo
  • Sanchez-Porro, Francisco J.
  • Crisman, Enrique
  • Cores, Ángel
  • Jiménez, Irene
  • Cuadrado, Antonio
  • Menéndez, J. Carlos
  • León, Rafael
Parkinson’s disease (PD), the second most common neurodegenerative disorder, affects around 10 million people worldwide. It is a multifactorial disease marked by dopaminergic neuron loss with oxidative stress (OS) and neuroinflammation as key pathological drivers. Current treatments focus on dopamine replacement and are symptomatic, underscoring the urgent need for disease-modifying therapies. Here, we present a novel class of dual MAO-B inhibitors and NRF2 inducers with neuroprotective properties in in vitro PD models. Through an optimization program, we enhanced their MAO-B inhibitory potency, selectivity, and NRF2 induction capacity while achieving favorable pharmacokinetic profiles. Virtual library screening identified two core derivatives, leading to the development of compound 11, which exhibited potent anti-inflammatory and neuroprotective activity in OS-related in vitro models. Compound 11 also demonstrated high liver microsomal stability and favorable pharmacokinetics in mice, making it a promising candidate for further investigation as a potential PD therapy., We are grateful for financial support from the Spanish Ministry of Health (Instituto de Salud Carlos III) (grant PI17/001700 and PI20/00433), the Spanish Ministry of Science (grant PID2021-123481OB-I00 to RL and PID2021-124983OB-I00) to JCM), and Comunidad de Madrid (grant P2022/BMD-7230-CAM-22 to RL). P.D. and F.J.S. thank MEC for FPU fellowships and E.C. thanks ISCIII for PFIS fellowship. The authors acknowledge the support from the European COST Action CA20121: Bench to bedside transition for the pharmacological regulation of NRF2 in noncommunicable diseases (BenBedPhar). Webpage: https://benbedphar.org/ about-benbedphar. The authors acknowledge technical support from Tomas Robredo with liver microsome experiments. We would also like to thank “Fundación Teófilo Hernando” for its continued support., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

Quinones as Neuroprotective Agents

  • Cores Esperón, Ángel
  • Carmona Zafra, Noelia
  • Clerigué Louzado, José
  • Villacampa Sanz, Mercedes
  • Menéndez Ramos, José Carlos
Quinones can in principle be viewed as a double-edged sword in the treatment of neurodegenerative diseases, since they are often cytoprotective but can also be cytotoxic due to covalent and redox modification of biomolecules. Nevertheless, low doses of moderately electrophilic quinones are generally cytoprotective, mainly due to their ability to activate the Keap1/Nrf2 pathway and thus induce the expression of detoxifying enzymes. Some natural quinones have relevant roles in important physiological processes. One of them is coenzyme Q10, which takes part in the oxidative phosphorylation processes involved in cell energy production, as a proton and electron carrier in the mitochondrial respiratory chain, and shows neuroprotective effects relevant to Alzheimer’s and Parkinson’s diseases. Additional neuroprotective quinones that can be regarded as coenzyme Q10 analogues are idobenone, mitoquinone and plastoquinone. Other endogenous quinones with neuroprotective activities include tocopherol-derived quinones, most notably vatiquinone, and vitamin K. A final group of non-endogenous quinones with neuroprotective activity is discussed, comprising embelin, APX-3330, cannabinoid-derived quinones, asterriquinones and other indolylquinones, pyrroloquinolinequinone and its analogues, geldanamycin and its analogues, rifampicin quinone, memoquin and a number of hybrid structures combining quinones with amino acids, cholinesterase inhibitors and non-steroidal anti-inflammatory drugs.